f5694sc13g.htm


SECURITIES AND EXCHANGE COMMISSION
Washington, DC  20549
 
SCHEDULE 13G
(Rule 13d-102)
 
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND
(d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2
(Amendment No.            )*
 
Vanda Pharmaceuticals Inc.
(Name of Issuer)
 
Common Stock, par value $0.001 per share
(Title of Class of Securities)
 
 
921659108
(CUSIP Number)
 
 
 
May 6, 2009
(Date of Event Which Requires Filing of This Statement)
 
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
o           Rule 13d-1(b)
 
ý           Rule 13d-1(c)
 
o           Rule 13d-1(d)
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 


 
Page 1 of 8 pages

 
CUSIP No.  921659108
 
13G
Page 2 of 8 Pages
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
TANG CAPITAL PARTNERS, LP
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
(a)  ¨ 
(b)  ý 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
DELAWARE
 
 
 
NUMBER OF
5
SOLE VOTING POWER
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
3,665,852
EACH REPORTING
PERSON WITH
 
7
SOLE DISPOSITIVE POWER
0
 
 
 
8
SHARED DISPOSITIVE POWER
3,665,852
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,665,852
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
¨
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
13.8%
 
12
TYPE OF REPORTING PERSON
 
PN
 
 
Page 2 of 8 pages

 
CUSIP No.  921659108
 
13G
Page 3 of 8 Pages
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
TANG CAPITAL MANAGEMENT, LLC
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
(a)  ¨ 
(b)  ý 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
DELAWARE
 
 
 
NUMBER OF
5
SOLE VOTING POWER
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
3,665,852
EACH REPORTING
PERSON WITH
 
7
SOLE DISPOSITIVE POWER
0
 
 
 
8
SHARED DISPOSITIVE POWER
3,665,852
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,665,852
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
¨
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
13.8%
 
12
TYPE OF REPORTING PERSON
 
OO
 
 
Page 3 of 8 pages

 
CUSIP No.  921659108
 
13G
Page 4 of 8 Pages
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
KEVIN C. TANG
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
(a)  ¨ 
(b)  ý 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
UNITED STATES
 
 
 
NUMBER OF
5
SOLE VOTING POWER
0
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
3,883,436
EACH REPORTING
PERSON WITH
 
7
SOLE DISPOSITIVE POWER
0
 
 
 
8
SHARED DISPOSITIVE POWER
3,965,852
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,965,852
 
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
¨
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
14.9%
 
12
TYPE OF REPORTING PERSON
 
IN
 
 
Page 4 of 8 pages

 
Item 1(a). Name of Issuer:
   
 
Vanda Pharmaceuticals Inc., a Delaware corporation (the “Issuer”)
   
Item 1(b).  Address of Issuer’s Principal Executive Offices:
   
 
9605 Medical Center Drive, Suite 300, Rockville, MD 20850
   
Item 2(a).    Name of Person Filing:
   
 
This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin C. Tang, the manager of Tang Capital Management.
   
Item 2(b).  Address of Principal Business Office or, if none, Residence:
   
 
4401 Eastgate Mall, San Diego, CA 92121
   
Item 2(c).   Citizenship:
   
 
Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.
   
Item 2(d).  Title of Class of Securities:
   
 
Common Stock, par value $0.001 per share (the “Common Stock”)
   
Item 2(e).
CUSIP Number:  921659108

Item 3.  Not applicable.
    
Item 4.  Ownership.
     
 
(a)  Amount Beneficially Owned:
     
   
Tang Capital Partners.  Tang Capital Partners is the beneficial owner of 3,665,852 shares of Common Stock. Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin C. Tang.
     
   
Tang Capital Management. Tang Capital Management, as the general partner of Tang Capital Partners, may be deemed to beneficially own the 3,665,852 shares beneficially owned by Tang Capital Partners. Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin C. Tang.
     
   
Kevin C. Tang.  Kevin C. Tang may be deemed to beneficially own 3,965,852 shares of the Issuer’s Common Stock, comprising:
     
   
3,665,852 shares beneficially owned by Tang Capital Partners, for which Tang Capital Management, of which Mr. Tang is manager, serves as general partner.  Mr. Tang shares voting and dispositive power over such shares with Tang Capital Management and Tang Capital Partners.
       
    300,000 shares over which Mr. Tang has voting and/or dispositive power.
 
Page 5 of 8 pages

 
  
   
Mr. Tang disclaims beneficial ownership of all shares reported herein except to the extent of his pecuniary interest therein.
     
     
   
(b)    Percent of Class:
     
    Tang Capital Partners 
13.8%
    Tang Capital Management 
13.8%
    Kevin C. Tang 
14.9%
     
   
(c) Number of shares as to which such person has:
     
    (i) sole power to vote or to direct the vote:
   
   
   
   
   
      Tang Capital Partners 0 shares
      Tang Capital Management 0 shares
      Kevin C. Tang 0 shares
         
    (ii)  shared power to vote or to direct the vote:
         
      Tang Capital Partners
3,665,852 shares
      Tang Capital Management  
3,665,852 shares
      Kevin C. Tang 
3,883,436 shares
         
    (iii)  sole power to dispose or to direct the disposition of:
         
      Tang Capital Partners 0 shares
      Tang Capital Management 0 shares
      Kevin C. Tang 0 shares
         
    (iv) shared power to dispose or to direct the disposition of:
         
      Tang Capital Partners
3,665,852 shares
      Tang Capital Management
3,665,852 shares
      Kevin C. Tang
3,965,852 shares
         
         
 Item 5.  Ownership of Five Percent or Less of a Class.
   
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ¨
   
Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
   
  Not applicable
   
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
   
  Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
   
  Not applicable.
   
Item 9. Notice of Dissolution of Group.
   
  Not applicable.
 
Page 6 of 8 pages


Item 10.  Certification.
   
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 
 
 
Page 7 of 8 pages

 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
 Date:  
   May 7,2009  
  
   
   
TANG CAPITAL PARTNERS, LP
   
By:  Tang Capital Management, LLC, its General Partner
   
By:     
/s/ Kevin C. Tang  
 
Kevin C. Tang, Manager
 
 
  
TANG CAPITAL MANAGEMENT, LLC
   
By:    
/s/ Kevin C. Tang 
 
Kevin C. Tang, Manager
 
 
   
/s/ Kevin C. Tang 
 Kevin C. Tang
 
 
 
 
 
Page 8 of 8 pages 

                    
ex99_1.htm
Exhibit 99.1
 
JOINT FILING AGREEMENT
 
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value, of Vanda Pharmaceuticals Inc. and further agree to the filing of this agreement as an exhibit thereto.  In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.
 
Date: May 7, 2009
TANG CAPITAL PARTNERS, LP
 
     
 
By:  
Tang Capital Management, LLC  
 
 
Its:  
General Partner 
 
     
 
By:  
/s/ Kevin C. Tang
 
   
Name:  
Kevin C. Tang 
 
   
Title:  
Manager 
 
 
 
TANG CAPITAL MANAGEMENT, LLC
 
 
 
By:  
/s/ Kevin C. Tang
 
   
Name:  
Kevin C. Tang 
 
   
Title:  
Manager 
 
     
 
/s/ Kevin C. Tang
 
 
Name:  
Kevin C. Tang